Corpus overview


MeSH Disease

Human Phenotype


gender (1)

    displaying 1 - 3 records in total 3
    records per page

    Acute Pancreatitis HP Pancreatitis MESHD may Occur in COVID-19 Patients with Clearance of SARS-CoV-2 in Lung: A Case Report

    Authors: Hong Zhao; Junwei Su; Kaijin Xu; Yu Shi; Yunqing Qiu; Jifang Sheng

    doi:10.21203/ Date: 2020-08-20 Source: ResearchSquare

    Background: Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), is mostly causes lung damages, but also lead to gastroenterology injury MESHD. SARS-CoV-2 - associated acute pancreatitis HP pancreatitis MESHD has been reported, however, clearance of SARS-CoV-2 and the pancreatitis HP pancreatitis MESHD was not clear.Case presentation: A 62 year old diabetic MESHD female TRANS patient suffer from coronavirus diseases MESHD (COVID-19) and detection of SARS-CoV-2 turned negative on day 11 and day 12 in sputum. Two days latter, the patient was diagnosed with acute pancreatitis HP acute pancreatitis MESHD. Through the support treatment, the patient got better and discharged from our hospital 18 days later.Conclusions: Our case provided an initial view of SARS-CoV-2 infection MESHD with acute pancreatitis HP pancreatitis MESHD and the acute pancreatitis HP pancreatitis MESHD may occur in COVID-19 patients with clearance of SARS-CoV-2 in lung.

    Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity

    Authors: Markus Hoffmann; Heike Hofmann-Winkler; Joan C. Smith; Nadine Krueger; Lambert K. Sorensen; Ole S. Sogaard; Jorgen Bo Hasselstrom; Michael Winkler; Tim Hempel; Lluis Raich; Simon Olsson; Takashi Yamazoe; Katsura Yamatsuta; Hirotaka Mizuno; Stephan Ludwig; Frank Noe; Jason M. Sheltzer; Mads Kjolby; Stefan Poehlmann

    doi:10.1101/2020.08.05.237651 Date: 2020-08-05 Source: bioRxiv

    Antiviral therapy is urgently needed to combat the coronavirus disease MESHD 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). The protease inhibitor camostat mesylate inhibits SARS-CoV-2 infection MESHD of lung cells by blocking the virus-activating host cell protease TMPRSS2. Camostat mesylate has been approved for treatment of pancreatitis HP pancreatitis MESHD in Japan and is currently being repurposed for COVID-19 treatment. However, potential mechanisms of viral resistance as well as camostat mesylate metabolization and antiviral activity of metabolites are unclear. Here, we show that SARS-CoV-2 can employ TMPRSS2-related host cell proteases for activation and that several of them are expressed in viral target cells. However, entry mediated by these proteases was blocked by camostat mesylate. The camostat metabolite GBPA inhibited the activity of recombinant TMPRSS2 with reduced efficiency as compared to camostat mesylate and was rapidly generated in the presence of serum SERO. Importantly, the infection experiments in which camostat mesylate was identified as a SARS-CoV-2 inhibitor involved preincubation of target cells with camostat mesylate in the presence of serum SERO for 2 h and thus allowed conversion of camostat mesylate into GBPA. Indeed, when the antiviral activities of GBPA and camostat mesylate were compared in this setting, no major differences were identified. Our results indicate that use of TMPRSS2-related proteases for entry into target cells will not render SARS-CoV-2 camostat mesylate resistant. Moreover, the present and previous findings suggest that the peak concentrations of GBPA established after the clinically approved camostat mesylate dose (600 mg/day) will result in antiviral activity.

    Highly ACE2 Expression in Pancreas May Cause Pancreas Damage MESHD After SARS-CoV-2 Infection MESHD

    Authors: Furong Liu; Xin Long; Wenbin Zou; Minghao Fang; Wenjuan Wu; Wei Li; Bixiang Zhang; Wanguang Zhang; Xiaoping Chen; Zhanguo Zhang

    doi:10.1101/2020.02.28.20029181 Date: 2020-03-03 Source: medRxiv

    The ongoing outbreak of coronavirus disease MESHD 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) started in the end of 2019 in China has triggered a global public health crisis. Previous studies have shown that SARS-CoV-2 infects MESHD cells by binding angiotensin-converting enzyme 2 (ACE2), which is the same as SARS-CoV MESHD. The expression and distribution of ACE2 in the pancreas are unknown. At the same time, the injury of pancreas MESHD after SARS-CoV-2 infection MESHD has not been concerned. Here, we collected public datasets (bulk RNA-seq and single-cell RNA-seq) to indicate the expression and the distribution of ACE2 in pancreas (in both exocrine glands and islets). And further, clinical data including mild and severe patients with COVID-19 demonstrated there existed mild pancreatitis HP pancreatitis MESHD. In the 67 severe cases, 11 patients (16.41%) showed elevated levels of both amylase and lipase, and 5 patients (7.46%) showed imaging alterations. Only one patient (1.85%) showed elevated levels of both amylase and lipase in 54 mild cases, without imaging changes. Our study revealed the phenomenon and possible cause of mild pancreatic injury MESHD in patients with COVID-19. This suggests that pancreatitis HP pancreatitis MESHD after SARS-CoV-2 infection MESHD should also be paid attention in clinical work.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.